Out of the lab, into the marketplace
Globe and Mail features AmacaThera’s Series A financingRead more
AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute
adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.Read more
AmacaThera named CIX Top 20 Early company
Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021.Read more
CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly Shoichet
ICYMI: Thanks to CBC's Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.Read more
AmacaThera Announces Close of Oversubscribed Series A Financing
Clinical trials set to begin on their proprietary drug delivery platform addresses key problem in sustained therapeutic delivery and is applicable to numerous disease indications and therapeutic modalities.Read more
Professor Molly Shoichet awarded the Gerzhard Herzberg Canada Gold Medal
Biomedical engineer’s novel hydrogel designs useful for regenerative medicine.Read more
AmacaThera Secures Funding to Initiate Phase I Trial of Non-Opioid Pain Control Therapeutic
AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners.Read more
Ontario Names Molly Shoichet the Province's First Chief Scientist
Shoichet Will Help Accelerate Scientific Innovation and Advance Science in Government Decision-Making.Read more